Protagen launches NavigAID SSc
“The World Scleroderma Foundation reports that approximately 2.5 million individuals worldwide suffer from SSc, which in its more aggressive form is the most fatal of all rheumatologic disorders,” Protagen Chairman of the Board of Directors Bernd Kirschbaum said. “Unfortunately, the extreme clinical diversity of the disease means that no two patients are truly alike, a fact that has hindered much-needed medical progress. Addressing the SSc heterogeneity challenge is crucial for the clinical development of effective and curative therapies. The new NavigAID SSc does exactly this.”
NavigAID SSc is the newest product in Proagen’s NavigAID line of products, following NavigAID SLE, which was released in 2015. NavigAID SSc allows for the specific segregation of patient subgroups through the measurement of serum biomarkers.
This allows for the likelihood of success in the treatment of SSc as well as in the development of clinical drugs. More specifically, NavigAID SSc was designed to take on the heterogeneity challenge linked to SSc.